Clinical Trials Logo
  1. Home
  2. Metastases
  3. NCT00265200
  4. Details
NCT00265200 Clinical Trial

Using TRAP to Evaluate the Effect of Zometa on Bone Metastasis Due to Lung Cancer

Metastases Clinical Trial

Official title:
Bone Metabolic Markers, TRAP, and Zometa's Effect on Bone Metastasis Due to Lung Cancer

Clinical Trial Details — Status: Terminated

Administrative data
NCT number NCT00265200
Other study ID # 565.04
Secondary ID BCC-LUN-04-002
Status Terminated
Phase Phase 2
First received December 12, 2005
Last updated March 1, 2018
Start date February 2005
Est. completion date December 2010

Study information
Verified date March 2018
Source University of Louisville
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate a new blood test as a way to follow the effect of Zometa in treating bone metastases due to lung cancer.

Description:

The purpose of this research study is to evaluate a new blood test as a way to follow the effect of Zometa in treating bone metastases. The blood test will look for a protein, called TRAP, which is released into the blood stream by the breakdown of bone. This study will compare the TRAP blood test with other blood tests for bone destruction.

Recruitment information / eligibility
Status Terminated
Enrollment 28
Est. completion date December 2010
Est. primary completion date August 2009
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- invasive lung cancer (small cell or non-small cell lung cancer)

- osteolytic bone metastasis determined by clinical exam, bone scan/XR

- age > 18 years

Exclusion Criteria:

- concurrent malignancy with a second primary

- renal failure (serum creatinine > 3mg/dl)

- pregnancy

- active rheumatoid arthritis

- intolerance to zoledronic acid

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• zoledronic acid
3.0-4.0 mg by IV (in the vein), once a month for 6 months

Locations
Country Name City State
United States James Graham Brown Cancer Center Louisville Kentucky

Sponsors (3)
Lead Sponsor Collaborator
University of Louisville James Graham Brown Cancer Center, Novartis Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary Average Percent Change From Baseline in TRAP Levels at 2 Weeks Change was calculated as 100% (value at baseline minus value at 2 weeks)/value at baseline TRAP levels at Baseline and 2 weeks after first Zometa infusion
See also
  Status Clinical Trial Phase
Completed NCT02156700 - Quantitative Real-time Ultrasound Elastography for Characterisation of Liver Tumors N/A
Terminated NCT01403324 - Comparison of Dosimetry After rhTSH or Withdrawal of Thyroid Hormone in Metastatic or Locally Advanced Thyroid Cancer N/A
Completed NCT00091832 - Denosumab (AMG 162) in Bisphosphonate Naive Metastatic Breast Cancer Phase 2
Completed NCT00094653 - MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma Phase 3
Completed NCT00080301 - Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer Phase 3
Completed NCT00446446 - PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer) Phase 2
Completed NCT01678664 - Everolimus After (Chemo)Embolization for Liver Metastases From Digestive Endocrine Tumors Phase 2
Completed NCT00083720 - Erbitux (Cetuximab) Given Alone to Patients With EGFR-Negative Metastatic Colon or Rectal Cancer That is Refractory to Chemotherapy Phase 2
Completed NCT00093080 - Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED) Phase 2
Completed NCT00096967 - A Study to Evaluate Avastin in Patients Treated in a Previous Genentech-Sponsored Cancer Study Phase 3
Completed NCT00097487 - A Study of Patients With HER2 Gene Amplified Metastatic Breast Cancer Treated With First Line Herceptin and a Taxane N/A
Completed NCT00752570 - A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma Phase 2
Recruiting NCT05195710 - Preoperative Y-90 Radioembolization for Tumor Control and Future Liver Remnant Hypertrophy in Patients With Colorectal Liver Metastases Phase 1
Completed NCT00106418 - A Research Study for Patients With Prostate Cancer Phase 2
Not yet recruiting NCT04825470 - Liver Transplantation for Unresectable GIST Liver Metastases N/A
Active, not recruiting NCT02414269 - Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin Phase 1/Phase 2
Terminated NCT01759238 - Chemoradiotherapy for Patients With Oligometastatic Colorectal Cancer Phase 2
Completed NCT00107861 - Interferon-Beta Gene Transfer (Ad.hIFN-β) as Treatment for Refractory Colorectal Carcinoma With Liver Metastases Phase 1/Phase 2
Completed NCT00095108 - Study of Interleukin-21 for Metastatic Malignant Melanoma and Metastatic Kidney Cancer Phase 1
Terminated NCT00099281 - DPPE in Combination With Epirubicin and Cyclophosphamide in the Treatment of Breast Cancer Phase 3

External Links